Boardroom Alpha Digest: Weds, Mar 1

by | Mar 1, 2023

Executive News

  • Richard De Schutter and Dr. Argeris Karabelas will step down from the Board of Bausch Health Companies (BHC)
  • Robert William Bennett officially took over as CEO and a Director at Innovative Food Holdings Inc. (IVFH)
  • Sean Menke, CEO of Sabre Corporation (SABR), will transition the CEO role to Kurt J. Ekert who is the current President. Menke will remain Executive Chair of the Board


  • Amidst an potential proxy battle with Elliott Investments, Salesforce (CRM) shares surged after hours on a strong earnings report

IPOs Upcoming

  • Opti-Harvest (OPHV) is looking at price ~$6.5M at a $3.5 – $4.0 range
  • NAVA HEALTH MD, LLC (NAVA) is looking to price $8.1M at $5 per share
  • Ultimax Digital, Inc. (NFTX) is looking to price ~$8.5M at a $4.0 – $5.0 range


  • Sagalim Acquisition Corp. (SAGA) and Saudi Arabia Entertainment Corp.‘s merger agreement was called off by AEC due to the SPAC’s inability to raise enough committed financing to meet 50% of the min. cash requirement. The SPAC’s CEO is fighting a $1mm termination fee and attempting to sell its interest in the SPAC.
  • Capitalworks Emerging Markets Acquisition (CMCA) and Lexasure Financial agreed to combine in a business combination agreement

SPAC Calendar

<a href="" target="_self">David Drapkin</a>

David Drapkin

Spent his formative years at Goldman Sachs and now embraces the start-up life in NYC. A long suffering Oakland (Las Vegas) Raiders fan and graduate of the Wharton School at the University of Pennsylvania. Semi-professional go-kart racer waiting for his shot.

Know Who Drives Return

Objective, data-driven assessments for every public company director and officer.

SPAC Analytics & Database

Comprehensive research and analytics on every SPAC, sponsor, and deal. Real-time alerts, yields, red flags, filings, investors, and much more. API access to institutional grade SPAC database.

Monthly SPAC Review

SPAC Market Review – January 2023

It was a slower month to kick off the year for SPACs. In what stands to be a pivotal year for the future of the market, we recap January.

SPAC Market Review – December 2022

December’s SPAC market review takes a look by the numbers of the month’s SPAC activity and how the market currently stands going into 2023.

SPAC Research & Analysis

Boardroom Alpha Digest: Thurs, Mar 9

Biogen Inc. (BIIB) chairman Stelios Papadopoulos will not stand for reelection at the annual meeting, and other highlights of the day.

Boardroom Alpha Digest: Thurs, Feb 9

Nelzon Peltz and Trian dropped their proxy fight against Walt Disney Co. (DIS) following Disney’s cost cutting, reorg, and board appointments.

Know Who Drives Return Podcast


The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon. 

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.  

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by BA that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.  

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.